Brinker Capital Investments’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.1M Sell
419,584
-26,907
-6% -$704K 0.08% 218
2026
Q1
$12.5M Sell
446,491
-58,759
-12% -$1.56M 0.11% 169
2025
Q4
$12.6M Buy
505,250
+32,206
+7% +$812K 0.09% 195
2025
Q3
$12.1M Sell
473,044
-236,206
-33% -$5.83M 0.09% 188
2025
Q2
$17.2M Buy
709,250
+40,805
+6% +$952K 0.15% 124
2025
Q1
$16.9M Buy
668,445
+86,175
+15% +$2.25M 0.17% 114
2024
Q4
$15.4M Buy
582,270
+29,552
+5% +$802K 0.15% 122
2024
Q3
$16M Sell
552,718
-32,991
-6% -$962K 0.16% 127
2024
Q2
$16.4M Buy
585,709
+27,141
+5% +$747K 0.17% 116
2024
Q1
$15.5M Buy
558,568
+71,493
+15% +$1.98M 0.17% 126
2023
Q4
$14.4M Sell
487,075
-101,509
-17% -$3.07M 0.17% 126
2023
Q3
$19.5M Sell
588,584
-83,394
-12% -$2.95M 0.24% 88
2023
Q2
$24.6M Buy
671,978
+7,003
+1% +$273K 0.26% 67
2023
Q1
$27.1M Buy
664,975
+258,150
+63% +$11.1M 0.33% 53
2022
Q4
$20.8M Buy
406,825
+15,873
+4% +$761K 0.42% 47
2022
Q3
$17.1M Sell
390,952
-8,855
-2% -$430K 0.35% 59
2022
Q2
$21M Buy
399,807
+7,289
+2% +$371K 0.4% 46
2022
Q1
$20.3M Buy
392,518
+75,947
+24% +$3.94M 0.31% 60
2021
Q4
$18.7M Buy
316,571
+18,878
+6% +$935K 0.27% 79
2021
Q3
$11.7M Buy
297,693
+8,011
+3% +$355K 0.19% 112
2021
Q2
$11.3M Buy
289,682
+44,574
+18% +$1.73M 0.15% 148
2021
Q1
$8.88M Sell
245,108
-21,142
-8% -$751K 0.13% 165
2020
Q4
$9.8M Sell
266,250
-166,814
-39% -$6.12M 0.15% 149
2020
Q3
$15.1M Buy
433,064
+393,578
+997% +$13.8M 0.26% 88
2020
Q2
$1.23M Buy
39,486
+25,994
+193% +$883K 0.05% 194
2020
Q1
$418K Buy
13,492
+1,409
+12% +$48K 0.02% 255
2019
Q4
$449K Buy
12,083
+1,336
+12% +$47.6K 0.02% 272
2019
Q3
$366K Buy
10,747
+8,757
+440% +$318K 0.01% 286
2019
Q2
$82K Buy
1,990
+885
+80% +$35.1K ﹤0.01% 522
2019
Q1
$45K Sell
1,105
-717
-39% -$28.7K ﹤0.01% 484
2018
Q4
$75K Buy
1,822
+8
+0.4% +$332 ﹤0.01% 361
2018
Q3
$76K Sell
1,814
-32
-2% -$1.23K ﹤0.01% 338
2018
Q2
$64K Buy
1,846
+553
+43% +$18.9K ﹤0.01% 354
2018
Q1
$44K Buy
1,293
+527
+69% +$18.1K ﹤0.01% 361
2017
Q4
$26K Sell
766
-42
-5% -$1.43K ﹤0.01% 387
2017
Q3
$27K Buy
808
+276
+52% +$8.87K ﹤0.01% 375
2017
Q2
$17K Sell
532
-272
-34% -$8.58K ﹤0.01% 378
2017
Q1
$26K Hold
804
﹤0.01% 340
2016
Q4
$25K Sell
804
-228
-22% -$6.96K ﹤0.01% 335
2016
Q3
$33K Buy
1,032
+272
+36% +$9.1K ﹤0.01% 311
2016
Q2
$25K Hold
760
﹤0.01% 316
2016
Q1
$21K Sell
760
-422
-36% -$12.1K ﹤0.01% 326
2015
Q4
$36K Buy
1,182
+106
+10% +$3.33K ﹤0.01% 340
2015
Q3
$32K Hold
1,076
﹤0.01% 332
2015
Q2
$34K Sell
1,076
-672
-38% -$21.9K ﹤0.01% 320
2015
Q1
$58K Buy
1,748
+672
+62% +$21.4K ﹤0.01% 304
2014
Q4
$32K Sell
1,076
-5,593
-84% -$160K ﹤0.01% 316
2014
Q3
$187K Buy
6,669
+428
+7% +$12K 0.01% 238
2014
Q2
$176K Sell
6,241
-1,318
-17% -$37.6K 0.01% 258
2014
Q1
$230K Buy
7,559
+6,483
+603% +$193K 0.01% 250
2013
Q4
$31K Sell
1,076
-7,322
-87% -$213K ﹤0.01% 294
2013
Q3
$229K Buy
8,398
+499
+6% +$13.6K 0.01% 249
2013
Q2
$210K Buy
+7,899
New +$218K 0.01% 252

Other funds holding PFE

Brinker Capital Investments's PFE Position: Q2 2026 in Review

Brinker Capital Investments reduced its Pfizer (PFE) stake by 6% in Q2 2026, selling an estimated $704K and leaving 419,584 shares worth $10.1M. The position accounts for 0.08% of the portfolio, ranked #218.

Brinker Capital Investments first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $27.1M in Q1 2023. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Brinker Capital Investments held 419,584 shares of Pfizer worth $10.1M as of Q2 2026.
  • Brinker Capital Investments sold 26,907 Pfizer shares in Q2 2026, an estimated $704K.
  • Pfizer made up 0.08% of Brinker Capital Investments's portfolio in Q2 2026, its #218 holding.
  • Brinker Capital Investments first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Brinker Capital Investments's Pfizer position peaked at $27.1M in Q1 2023.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.